Sino Medical Sciences Technology In Net Assets
Sino Medical Sciences Technology In net assets. Based on the latest financial reports, Sino Medical Sciences Technology In (688108) has net assets worth CN¥1.07 Billion CNY (≈ $156.88 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.36 Billion ≈ $198.69 Million USD) and total liabilities (CN¥285.74 Million ≈ $41.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 688108 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.07 Billion |
| % of Total Assets | 78.96% |
| Annual Growth Rate | 30.86% |
| 5-Year Change | 141.38% |
| 10-Year Change | N/A |
| Growth Volatility | 73.57 |
Net Assets of Sino Medical Sciences Technology In (2016–2025)
Net assets of Sino Medical Sciences Technology In from 2016 to 2025. This chart illustrates how Sino Medical Sciences Technology In's net assets have evolved over time, based on quarterly financial data. See 688108 equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Sino Medical Sciences Technology In (2016–2025)
The table below shows the annual net assets of Sino Medical Sciences Technology In from 2016 to 2025. For live market cap and overall valuation, see Sino Medical Sciences Technology In market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.28 Billion ≈ $333.85 Million |
+153.97% |
| 2024-12-31 | CN¥898.34 Million ≈ $131.46 Million |
+4.26% |
| 2023-12-31 | CN¥861.65 Million ≈ $126.09 Million |
-2.91% |
| 2022-12-31 | CN¥887.48 Million ≈ $129.87 Million |
-6.10% |
| 2021-12-31 | CN¥945.16 Million ≈ $138.31 Million |
-12.31% |
| 2020-12-31 | CN¥1.08 Billion ≈ $157.73 Million |
-1.88% |
| 2019-12-31 | CN¥1.10 Billion ≈ $160.75 Million |
+56.64% |
| 2018-12-31 | CN¥701.28 Million ≈ $102.62 Million |
+15.59% |
| 2017-12-31 | CN¥606.70 Million ≈ $88.78 Million |
+199.24% |
| 2016-12-31 | CN¥202.75 Million ≈ $29.67 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sino Medical Sciences Technology In's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13934927679.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Sino Medical Sciences Technology In Net Assets Breakdown (December 2025)
Sino Medical Sciences Technology In net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | CN¥900.75 Million | 96.67% |
| Other Components | CN¥224.59 Million | 24.10% |
| Total Equity | CN¥931.81 Million | 100.00% |
Sino Medical Sciences Technology In Competitors by Market Cap
The table below lists competitors of Sino Medical Sciences Technology In ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yieh Phui Enterprise Co Ltd
TW:2023
|
$846.93 Million |
|
SP Group A/S
CO:SPG
|
$847.53 Million |
|
Chutian Dragon Co Ltd
SHE:003040
|
$847.53 Million |
|
Zhongtong Bus Holding Co Ltd
SHE:000957
|
$847.65 Million |
|
Shenzhen Farben Information Technology Co.Ltd.
SHE:300925
|
$846.28 Million |
|
Zhejiang Kaier New Materials
SHE:300234
|
$846.01 Million |
|
Ningbo Sunrise Elc Technology Co Ltd Class A
SHE:002937
|
$845.78 Million |
|
Mivtach Shamir
TA:MISH
|
$845.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sino Medical Sciences Technology In's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 866,885,685 to 931,814,372, a change of 64,928,687 (7.5%).
- Net income of 47,286,300 contributed positively to equity growth.
- Dividend payments of 4,194,500 reduced retained earnings.
- Other comprehensive income increased equity by 848,732,809.
- Other factors decreased equity by 826,895,922.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥47.29 Million | +5.07% |
| Dividends Paid | CN¥4.19 Million | -0.45% |
| Other Comprehensive Income | CN¥848.73 Million | +91.08% |
| Other Changes | CN¥-826.90 Million | -88.74% |
| Total Change | CN¥- | 7.49% |
Book Value vs Market Value Analysis
This analysis compares Sino Medical Sciences Technology In's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.70x to 6.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥1.01 | CN¥13.84 | x |
| 2017-12-31 | CN¥2.32 | CN¥13.84 | x |
| 2018-12-31 | CN¥1.97 | CN¥13.84 | x |
| 2019-12-31 | CN¥2.93 | CN¥13.84 | x |
| 2020-12-31 | CN¥2.63 | CN¥13.84 | x |
| 2021-12-31 | CN¥2.27 | CN¥13.84 | x |
| 2022-12-31 | CN¥2.09 | CN¥13.84 | x |
| 2023-12-31 | CN¥2.07 | CN¥13.84 | x |
| 2024-12-31 | CN¥2.32 | CN¥13.84 | x |
| 2025-12-31 | CN¥2.17 | CN¥13.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sino Medical Sciences Technology In utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.07%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.00%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.45x
- Recent ROE (5.07%) is above the historical average (1.52%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 14.13% | 10.79% | 0.95x | 1.39x | CN¥8.38 Million |
| 2017 | 10.90% | 20.54% | 0.45x | 1.17x | CN¥5.48 Million |
| 2018 | 12.72% | 23.45% | 0.47x | 1.15x | CN¥19.06 Million |
| 2019 | 8.20% | 20.65% | 0.36x | 1.10x | CN¥-19.81 Million |
| 2020 | 2.09% | 6.87% | 0.27x | 1.13x | CN¥-85.29 Million |
| 2021 | -14.09% | -67.28% | 0.18x | 1.19x | CN¥-223.55 Million |
| 2022 | -19.17% | -84.20% | 0.18x | 1.26x | CN¥-247.09 Million |
| 2023 | -4.83% | -11.55% | 0.29x | 1.45x | CN¥-121.63 Million |
| 2024 | 0.17% | 0.33% | 0.35x | 1.50x | CN¥-85.19 Million |
| 2025 | 5.07% | 9.00% | 0.39x | 1.45x | CN¥-45.90 Million |
Industry Comparison
This section compares Sino Medical Sciences Technology In's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,728,515,784
- Average return on equity (ROE) among peers: 10.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sino Medical Sciences Technology In (688108) | CN¥1.07 Billion | 14.13% | 0.27x | $846.45 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $3.98 Billion | -16.09% | 0.31x | $384.61 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $143.67 Million | 40.91% | 1.23x | $4.24 Billion |
| Double Medical Technology Inc (002901) | $2.59 Billion | 26.01% | 0.31x | $2.56 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $5.66 Billion | -0.29% | 0.06x | $494.04 Million |
| Lepu Medical Tech Beijing (300003) | $8.00 Billion | 21.55% | 0.99x | $3.40 Billion |
| INKON Life Technology Co Ltd (300143) | $727.00 Million | 5.81% | 0.17x | $817.03 Million |
| Edan Instruments Inc (300206) | $1.23 Billion | 2.15% | 0.20x | $1.02 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $393.88 Million | 7.34% | 0.20x | $505.98 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.09 Billion | 11.74% | 0.48x | $473.66 Million |
| Sinocare Inc (300298) | $3.47 Billion | 8.19% | 0.71x | $1.56 Billion |
About Sino Medical Sciences Technology In
Sino Medical Sciences Technology Inc., a medical device company, engages in the research, development, production, and distribution of interventional medical devices in China. Its products include coronary drug stents, coronary balloons catheter, intracranial rapid exchange balloons, and intracranial drug-eluting stents, as well as transapical mitral valve replacement system. Sino Medical Science… Read more